



Communication

Different Impacts of Cryopreservation in Endothelial and Epithelial Ovarian Cells

Julian Marschalek ¹, Marlene Hager ¹, Sophie Wanderer ², Johannes Ott ¹ , Maria Frank ¹, Christian Schneeberger ¹ and Detlef Pietrowski ^{1,*}

¹ Department of Obstetrics and Gynecology, Medical University of Vienna, Spitalgasse 23, 1090 Vienna, Austria; julian.marschalek@meduniwien.ac.at (J.M.); marlene.hager@meduniwien.ac.at (M.H.); johannes.ott@meduniwien.ac.at (J.O.); maria.frank@meduniwien.ac.at (M.F.); christian.schneeberger@meduniwien.ac.at (C.S.)

² FH Campus Wien, University of Applied Science, 1100 Vienna, Austria

* Correspondence: detlef.pietrowski@meduniwien.ac.at; Tel.: +00431-40400-78740; Fax: +00431-40400-28170

Abstract: The aim of our laboratory-based study was to investigate the extent of delayed-onset cell death after cryopreservation in endothelial and epithelial cell lines of ovarian origin. We found differences in percentages of vital cells directly after warming and after cultivation for 48 to 72 h. A granulosa cell line of endothelial origin (KGN) and an epithelial cell line (OvCar-3) were used. In both DMSO-containing and DMSO-free protocols, significant differences in vitality rates between the different cell lines when using open and closed vitrification could be shown (DMSO-containing: KGN open vs. OvCar open, $p = 0.001$; KGN closed vs. OvCar closed, $p = 0.001$; DMSO-free: KGN open vs. OvCar open, $p = 0.001$; KGN closed vs. OvCar closed, $p = 0.031$). Furthermore, there was a marked difference in the percentage of vital cells immediately after warming and after cultivation for 48 to 72 h; whereas the KGN cell line showed a loss of cell viability of 41% using a DMSO-containing protocol, the OvCar-3 cell loss was only 11% after cultivation. Using a DMSO-free protocol, the percentages of late-onset cell death were 77% and 48% for KGN and OvCar-3 cells, respectively. Our data support the hypothesis that cryopreservation-induced damage is cell type and cryoprotective agent dependent.

Keywords: cryopreservation; vitrification; dimethyl sulfoxide (DMSO); cryopreservation-induced delayed-onset cell death; granulosa cell



Citation: Marschalek, J.; Hager, M.; Wanderer, S.; Ott, J.; Frank, M.; Schneeberger, C.; Pietrowski, D. Different Impacts of Cryopreservation in Endothelial and Epithelial Ovarian Cells. *Int. J. Mol. Sci.* **2023**, *24*, 12225. <https://doi.org/10.3390/ijms241512225>

Academic Editors: Gábor L. Kovács, Emese Mezösi and Dénes Molnár

Received: 4 July 2023
Revised: 27 July 2023
Accepted: 29 July 2023
Published: 31 July 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Cryopreservation of ovarian tissue is an increasingly applied method for fertility preservation in patients undergoing gonadotoxic therapies, and has led to the birth of more than 200 children so far [1,2]. In general, there are slow and fast freezing methods. Vitrification, an ultra-fast freezing method, is promising, and probably cost-effective [3]. The process of cryopreservation is complex, and, especially in basic research, the evaluation of its success is usually based on sample assessment immediately after warming [4–6].

When storing biological living cells and tissues at cryogenic temperatures, cells are exposed to physical and chemical stressors, such as cold and osmotic stress, or the formation of intracellular and extracellular ice crystals. Regardless of advancements in cryopreservation protocols, the potential toxicity of cryoprotective agents is also reported to play a role in the development of cryopreservation-induced injuries. As most cryoinjuries occur during freezing and warming processes, cell death after warming is still substantial, and occurs mostly within the first 24 h of culturing [7].

Furthermore, cryopreservation-induced delayed-onset cell death (CIDOCD) is a regularly observed phenomenon in cryopreservation, which occurs at a molecular level via apoptotic and necrotic processes, and hours after an apoptosis-triggering event. Cell loss is

reported to be as high as 70% of cells when examined 24–48 h after warming [4,8]. A number of studies have shown that CIDOCD is not only cell-type specific, but also dependent upon the growth phase of the respective cells and the cryoprotective agent used [9,10].

Thus, evaluating the effectivity of a cryopreservation via sample assessment immediately after warming only has informative value to a limited extent [4].

As stated above, an upcoming and alternative method of cryopreserving ovarian tissue is vitrification, an ultra-fast freezing method that prevents cell-damaging ice crystal formation. Despite promising research results in human and animal studies indicating similar outcomes compared to the conventional slow freezing method, there are no established standard vitrification protocols yet [11]. The most significant differences in published protocols are the different CPAs used and the times required for respective equilibration steps [12,13]. The most popular CPAs are dimethyl sulfoxide (DMSO), glycerol, propanediol (PrOH), and ethylene glycol (EG), which are necessary to achieve controlled cell dehydration before cryopreservation. For this step, the mentioned permeating agents are used together with non-permeating agents, which include proteins, sugars, and other macromolecules [14]. Notably, CPAs themselves can have a dose-dependent toxic effect on cells and their functions [15,16].

In this regard, it is still unclear whether dimethyl sulfoxide (DMSO), which is used in many protocols, is the most appropriate CPA for human reproductive tissue [17,18]. Moreover, it is still uncertain if open or closed vitrification devices result in better outcomes in oocyte, embryo, and ovarian tissue vitrification [19,20].

It must be taken into account that ovarian tissue consists of a multitude of different cells and cell types, mostly of epithelial and endothelial origin, of which the granulosa cells surrounding the follicle are particularly important for ovarian function. Of note, the individual effects of vitrification on a particular cell type have not been sufficiently investigated up to now. A few questions remain to be answered, including if the use of open or closed vitrification devices makes a difference concerning the vitrification of specific cell types, and whether late-onset cell death can also occur in vitrified ovarian tissue. If this is the case, it would be interesting to know which cell type is the most affected [19,21].

Thus, the aim of our study was to investigate the effects of open and closed vitrification devices with respect to vitality in endothelial and epithelial cell lines, using a DMSO-containing and a DMSO-free protocol.

2. Results

2.1. FACS Analysis

After vitrification using the DMSO-containing protocol and subsequent warming (Figure 1), 72.79% of KGN cells (KGN O) were vital using an open vitrification device. After closed vitrification, 74.56% of KGN cells (KGN CL) were vital (KGN O vs. KGN CL $p = 0.899$). There were 52.66% vital OvCar-3 cells (OvCar O) after open vitrification, and 39.1% vital OvCar-3 cells (OvCar CL) after closed vitrification (OvCar O vs. OvCar CL $p = 0.0746$).

A significant difference was found in the amount of vital cells resulting from open and closed vitrification with respect to the different cells used (KGN O vs. OvCar O $p = 0.001$; KGN CL vs. OvCar CL $p = 0.001$).

Using the DMSO-free vitrification protocol (Figure 2), 85.18% of KGN cells (KGN O) were vital using an open vitrification device, whereas 78.41% of KGN cells (KGN CL) were vital after closed vitrification (KGN O vs. KGN CL $p = 0.828$). The percentages of vital OvCar-3 cells were 63.57% (OvCar O) and 63.32% (OvCar CL) (OvCar O vs. OvCar CL $p = 0.899$).

There was a significant difference in KGN and OvCar cell vitality after open and closed vitrification (KGN O vs. OvCar O, $p = 0.001$; KGN CL vs. OvCar CL, $p = 0.031$).




Figure 1. Cell vitality using a DMSO-containing protocol determined using FACS analysis. Results of FACS analyses of human granulosa cells (KGN) and ovarian cancer cells (OvCar) after open (O) or closed (CL) cryopreservation in DMSO-containing CPA solution. Individual experiments were repeated five times. Values are indicated in % \pm SD.




Figure 2. Cell vitality using a DMSO-free protocol determined using FACS analysis. Results of FACS analyses of human granulosa cells (KGN) and ovarian cancer cells (OvCar) after open (O) or closed (CL) cryopreservation in DMSO-free CPA solution. Individual experiments were repeated five times. Values are indicated in % \pm SD.

2.2. Cell Cultivation for 48–72 h and Trypan Blue Staining

Trypan blue staining results are presented in Figures 3 and 4. With the DMSO-containing protocol warming and cultivation, 29.09% of KGN cells were vital using an open vitrification device (KGN O). After closed vitrification, 35.83% of KGN cells were vital (KGN CL). The percentages of vital OvCar-3 cells after cultivation were 42.77% (OvCar O) and 27.71% (OvCar CL).

After DMSO-free vitrification, warming, and cultivation, 5.41% of KGN cells were vital using an open vitrification device (KGN O). After closed vitrification, 4.54% of KGN cells were vital (KGN CL). When comparing open and closed vitrification methods, 16.54% (OvCar O) and 15.31% (OvCar CL) of OvCar-3 cells were vital, respectively.




Figure 3. Cell vitality using a DMSO-containing protocol after cultivation and trypan blue staining. Results of trypan blue vitality counting of human granulosa cells (KGN) and ovarian cancer cells (OV) after open (O) or closed (CL) cryopreservation in DMSO-containing CPA solution and cultivation. (n = 5; values are indicated in % ± SD; significant parameters are marked with an asterisk (** significance level < 0.01, * significance level < 0.05).




Figure 4. Cell vitality using a DMSO-free protocol after cultivation and trypan blue staining. Results of trypan blue vitality counting of human granulosa cells (KGN) and ovarian cancer cells (OV) after open (O) or closed (CL) cryopreservation in DMSO-free CPA solution and cultivation. (n = 5; values are indicated in % ± SD; significant parameters are marked with an asterisk; (** significance level < 0.01).

2.3. Total Cell-Specific Vitality Rate

The vitality rates of non-vital cells after vitrification and cultivation are presented in Table 1. They indicate that, using the DMSO-containing protocol, the percentage of non-vital cells after cultivation was lower in both KGN and OvCar-3 cell lines compared to using the DMSO-free protocol (41.22% and 10.64% vs. 76.82% and 47.52%, respectively). Comparing the percentages of non-vital cells in the open protocol and closed protocol, no clear differences were apparent (61.74% and 28.46% vs. 56.3% and 29.7%, respectively).

Table 1. *Vitality rates:* percentage of non-viable cells immediately after warming and after 48 h of cultivation, sorted according to the CPAs used and open and closed vitrification.

Cell Line	DMSO Cont.	No DMSO	Open	Closed
KGN	41.22	76.82	61.74	56.3
OvCar	10.64	47.52	28.46	29.7

3. Discussion

In this study, we investigated and quantified the extent of delayed-onset cell death after cryopreservation using vitrification in two different cell lines of ovarian origin.

The main finding of our study was a marked difference in the percentage of vital cells immediately after warming and after cultivation for 48 to 72 h in a cell-type specific manner. Whereas the KGN cell line showed a loss of cell viability of 41% using a DMSO-containing protocol, the OvCar-3 cell line seemed to be more resistant, as its cell loss was only 11% after cultivation. Using a DMSO-free protocol, the percentages of late-onset cell death were 77% and 48% for KGN and OvCar-3 cells, respectively.

After the warming process in cell cryopreservation, a low recovery rate of cells [4,22] or loss of proper cell function [23,24] are typical findings. Whereas a low recovery rate of cells directly after warming is mainly linked to cellular damage by intra-cellular ice crystal formation, osmotic pressure, apoptosis, or toxicity, the phenomenon of late-onset cell death after cryopreservation is different, and was first described by Baust and colleagues [8]. CIDCOD has been reported to occur later than 24 h after warming, and is primarily induced by apoptotic and/or necrotic processes.

The apoptosis-triggering processes of CIDCOD are reported to involve a genomic response via the up-regulation of key apoptotic enzymes of the caspase family [4] and increased caspase-3 and caspase-6 activity [25]. Moreover, decreased cytokine production and reduced lymphocyte growth were observed 72 h after cultivation in repeated cryopreservation/warming cycles. [6]. Our study group noted that the expression of tumor necrosis factor alpha (TNF-alpha), which is a key factor of late apoptosis modulating inflammatory reaction, was significantly increased after vitrification and subsequent warming in KGN cell lines [26].

Our results demonstrate a clear difference between the vitality of cells immediately after warming and at a later time point, supporting the involvement of CIDCOD. Of note, most articles regarding cell cryopreservation evaluate cell vitality solely directly after warming.

Another interesting observation from our study was the different sensitivities of specific cell types to CIPCOD. Whereas the endothelial granulosa cell line KGN showed a high amount of non-vital cells after 48 h, the OvCar-3 cells of epithelial origin seemed to be more robust with respect to CIDCOD. To the best of our knowledge, we are the first to describe these ovarian cell type-specific differences with respect to CIDCOD. This finding might be especially relevant with respect to ovarian tissue cryopreservation and re-transplantation in fertility preservation, as ovarian tissue consists of cells of both endothelial and epithelial origin. An explanation for the observed differences in the viability of the OvCar-3 and KGN cells could be that the cell lines originated from different tumors. Whereas the origin of the KGN cell line was a granulosa cell tumor from the pelvic region, the OvCar-3 cell line was derived from an adenocarcinoma that had been resistant to cisplatin while sensitive to a number of other chemotherapeutic agents. KGN cells, in contrast to OvCar-3 cells, have aromatase activity and the ability to release estrogen and progesterone. We hypothesize that this might protect KGN cells from apoptosis, as the finding that estrogen can suppress apoptosis and promote tumor cell proliferation has already been demonstrated for several estrogen-dependent cancer cell types [27].

Moreover, the use of DMSO as a cryoprotective agent seems to be a contributing factor for cell survival, as reported earlier [26,28].

Baust and others demonstrated that controlling the cellular stress response not only improves cell survival, but also cell function and repopulation after warming [5,29]. This could reduce the need for cryoprotective agents such as DMSO [30,31]. Recently, it was shown by Liu et al. that a pre-vitrification treatment of ovarian grafts using rapamycin, an inhibitor of the mTOR signaling pathway, could effectively prevent apoptosis and promote ovarian survival during ovarian tissue cryopreservation [32]. If and how a rapamycin pretreatment could be helpful in preventing CIDCOD remains to be evaluated in further studies.

As mentioned above, it is still uncertain if a better outcome results from open or closed vitrification methods [19,20,33,34]. Despite the fact that our sample size appears too small to ultimately answer this question, our data support the assumption of equality between open and closed vitrification methods. When comparing the vitality of KGN and OvCar-3 cells using open and closed vitrification methods, we observed a significant difference between the two cell lines with respect to DMSO-containing and DMSO-free protocols. However, we could not find a significant difference between open and closed vitrification for the respective cell lines.

Of course, our study has a few limitations that should be taken into account. In our in vitro model we used two cell lines derived from ovarian tumors. Such cell lines are typically no longer subject to division restriction. Hence, our results may only be applicable to carcinoma cells. Furthermore, ovarian tissue consists of a multitude of different cell types, which influence each other through cell-to-cell contacts, exchange of growth factors, and endocrine crosstalk. In our in vitro situation, cells were cultivated only one cell type at a time. Therefore, our findings seem to be comparable to the in vivo tissue to only a limited extent. Including a non-cancerous ovarian cell line in future studies might help clarify if the results can be generalized to non-cancerous ovarian tissue.

4. Materials and Methods

The effects of vitrification were evaluated directly after warming via fluorescence-activated cell sorting (FACS) analysis, and, with respect to CIDCOD, 48 to 72 h after warming and cell cultivation. A granulosa cell line of endothelial origin (KGN) and an epithelial cell line (OvCar-3) were used as models for endothelial and epithelial cell types in ovarian tissue, respectively. The human KGN granulosa cell line was a friendly gift from Katja Horling (Department of Anatomy and Cell Biology, Faculty of Medicine, Martin Luther University, Halle, Germany). The OvCar-3 cell line was a friendly gift from Dan Cacsire Castillo-Tong (Department of Obstetrics and Gynecology, Medical University of Vienna, Vienna, Austria). Except otherwise stated, all chemicals were obtained from Sigma (Sigma Chemical Co., St. Louis, MO, USA).

A schematic illustration of the experimental schedule is presented in Figure 5.




Figure 5. Experimental schedule for KGN and OvCar-3 cell lines. DMSO (+): DMSO-containing protocol; DMSO (-): DMSO-free protocol; FACS: fluorescence-activated cell sorting analysis; DAPI: 4,6 diamino-2-phenylindole-dihydrochloride.

4.1. Vitrification and Warming

We adapted two published protocols: one described by Silber et al. [35] containing DMSO as the CPA, and one by Oktem et al. [36], who used a DMSO-free protocol.

4.1.1. DMSO-Containing Vitrification Protocol

For vitrification using the DMSO-containing protocol (DMSO-containing), 10×10^6 cells were equilibrated for 5 min in a CPA solution containing 7.5% DMSO, 7.5% ethylene glycole (EG), and 20% fetal calf serum (FCS) in Dulbecco's modified Eagle's medium (DMEM). After centrifugation for 5 min at 300 rcf, the supernatant was discarded and the cells were incubated for 5 min in a solution containing 20% DMSO, 20% EG, 0.5 M sucrose, and 20% FCS in DMEM. After centrifugation, the supernatant was discarded and the cell pellets were cooled in a 1.8 mL tube (NUNC, Thermofisher Waltham, MA, USA) by direct immersion into liquid nitrogen (N_2). For open vitrification (O), the tube was closed after the N_2 step. For closed vitrification (CL), a lid was placed on the tube before immersion into liquid nitrogen.

4.1.2. DMSO-Free Vitrification Protocol

For vitrification using the DMSO-free protocol (DMSO-free), 10×10^6 cells were equilibrated for 10 min in a CPA solution containing 15% propanediol, 15% EG, 0.2 M sucrose, and 10% FCS in DMEM. After centrifugation for 5 min at 300 rcf, the supernatant was discarded and the cell pellets were cooled in a 1.8 mL tube (NUNC, Thermofisher Waltham, MA, USA) by direct immersion into liquid nitrogen (N_2). For open vitrification (O), the tube was closed after the N_2 step. For closed vitrification (CL), a lid was placed on the tube before immersion into liquid nitrogen.

4.1.3. Warming

Warming of all samples was performed by adding 1 mL of a warming solution at 37 °C (containing 1 M sucrose and 20% FCS) for 1 min in a water bath at 37 °C. After centrifugation for 5 min at 300 rcf, the supernatant was discarded and 1 mL of a solution containing 0.5 M sucrose and 20% FCS was added to the cell pellet for 3 min. After a further centrifugation step, the cells were suspended in phosphate buffered saline (PBS) containing 20% FCS.

4.2. Fluorescence-Activated Cell Sorting (FACS) Analysis

For FACS analysis, vitrified tubes were warmed according to the protocol above. After two washing steps using PBS, cells were suspended in 1 mL PBS. Analyses were performed using a BD FACSVerser Flow cytometer. 4,6 diamino-2-phenylindole-dihydrochloride (DAPI) was added to the samples 10 min before the analysis started. DAPI negative cells were classified as vital. Experiments were repeated at least five times individually, and a minimum of 10,000 events were collected. Data were analyzed using BD FACSuite V1.06 and FLOWJO software (www.flowjo.com, accessed on 1 June 2023).

4.3. Total Cell-Specific Vitality Rate

In the next step we calculated total cell-specific vitality rates depending on the protocol used (DMSO-containing vs. DMSO-free; open vs. closed vitrification) for all KGN cells and all OvCar-3 cells.

We determined the percentage of cells that died during the cultivation period by subtracting the value after cultivation from the value immediately after warming, which reflects the percentage of cells that died within 48 h. We therefore subtracted the amount of vital cells 48 h after cultivation from the total amount of vital cells determined immediately after warming (FACS).

4.4. Cell Cultivation and Trypan Blue Staining

Both cell lines, the human granulosa cell line, KGN, and the human ovarian carcinoma cell line, OvCar-3, were routinely cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) and a final concentration of 100 units/mL of penicillin and 100 µg/mL of streptomycin (1% Pen/Strep) at 37 °C with 5% CO_2 .

Approximately 1.5×10^6 KGN cells and 0.2×10^6 OvCar-3 cells were seeded in cell culture dishes (Sarsted, Nürnberg, Germany). After 48 to 72 h the vitality of the cells was determined using trypan blue staining in a Neubaur's counting chamber.

4.5. Statistical Analysis

Data from FACS analyses and results of trypan blue staining were analyzed using ANOVA for independent samples followed by Tukey's HSD Test on the Vassar Stat Homepage (www.Vassarstat.net). The rate of vital cells was handled as a numerical variable, and thus analysis of variances (ANOVA) was used to test this specific variable. ANOVA followed by a post hoc test is a frequently used statistical method to detect significances in FACS analyses dealing with apoptosis and necrosis. In our study, Tukey's HSD Test for post hoc analysis was used [37,38]. Differences were considered statistically significant at $p < 0.05$.

5. Conclusions

In conclusion, our results lend support to the hypothesis that cryopreservation-related damage is not only cell type dependent, but also dependent on the cryoprotective agent used. We believe that this observation requires further evaluation, especially in terms of ovarian tissue cryopreservation and subsequent re-transplantation.

Author Contributions: J.M., D.P., S.W., M.H., and J.O. contributed to the conception, design, analysis, and interpretation of data, and wrote the main text. D.P., M.F., and S.W. contributed to data generation and figure preparation. M.H., D.P., and C.S. contributed to data generation and interpretation of data. All authors have read and agreed to the published version of the manuscript.

Funding: Funding for this study was provided by the "Medical Scientific Fund of the Mayor of the City Vienna" (BM 17103).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data will be made available upon request.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Dolmans, M.M.; Falcone, T.; Patrizio, P. Importance of patient selection to analyze in vitro fertilization outcome with transplanted cryopreserved ovarian tissue. *Fertil. Steril.* **2020**, *114*, 279–280. [[CrossRef](#)] [[PubMed](#)]
2. Dolmans, M.M.; von Wolff, M.; Poirot, C.; Diaz-Garcia, C.; Cacciottola, L.; Boissel, N.; Liebenthron, J.; Pellicer, A.; Donnez, J.; Andersen, C.Y. Transplantation of cryopreserved ovarian tissue in a series of 285 women: A review of five leading European centers. *Fertil. Steril.* **2021**, *115*, 1102–1115. [[CrossRef](#)] [[PubMed](#)]
3. Suzuki, N.; Yoshioka, N.; Takae, S.; Sugishita, Y.; Tamura, M.; Hashimoto, S.; Morimoto, Y.; Kawamura, K. Successful fertility preservation following ovarian tissue vitrification in patients with primary ovarian insufficiency. *Hum. Reprod.* **2015**, *30*, 608–615. [[CrossRef](#)]
4. Baust, J.M.; Van, B.; Baust, J.G. Cell viability improves following inhibition of cryopreservation-induced apoptosis. *Vitr. Cell. Dev. Biol. Anim.* **2000**, *36*, 262–270. [[CrossRef](#)]
5. Baust, J.M.; Snyder, K.K.; Van Buskirk, R.G.; Baust, J.G. Assessment of the Impact of Post-Thaw Stress Pathway Modulation on Cell Recovery following Cryopreservation in a Hematopoietic Progenitor Cell Model. *Cells* **2022**, *11*, 278. [[CrossRef](#)]
6. Serra, V.; Fiorillo, E.; Cucca, F.; Orrù, V. Quantifying the Detrimental Effects of Multiple Freeze/Thaw Cycles on Primary Human Lymphocyte Survival and Function. *Int. J. Mol. Sci.* **2022**, *24*, 634. [[CrossRef](#)]
7. Bissoyi, A.; Nayak, B.; Pramanik, K.; Sarangi, S.K. Targeting cryopreservation-induced cell death: A review. *Biopreserv. Biobank.* **2014**, *12*, 23–34. [[CrossRef](#)]
8. Baust, J.M.; Vogel, M.J.; Van Buskirk, R.; Baust, J.G. A molecular basis of cryopreservation failure and its modulation to improve cell survival. *Cell Transplant.* **2001**, *10*, 561–571. [[CrossRef](#)]
9. Nagle, W.A.; Soloff, B.L.; Moss, A.J., Jr.; Henle, K.J. Cultured Chinese hamster cells undergo apoptosis after exposure to cold but nonfreezing temperatures. *Cryobiology* **1990**, *27*, 439–451. [[CrossRef](#)]
10. Soloff, B.L.; Nagle, W.A.; Moss, A.J., Jr.; Henle, K.J.; Crawford, J.T. Apoptosis induced by cold shock in vitro is dependent on cell growth phase. *Biochem. Biophys. Res. Commun.* **1987**, *145*, 876–883. [[CrossRef](#)]

11. Kometas, M.; Christman, G.M.; Kramer, J.; Rhoton-Vlasak, A. Methods of Ovarian Tissue Cryopreservation: Is Vitrification Superior to Slow Freezing?—Ovarian Tissue Freezing Methods. *Reprod. Sci.* **2021**, *28*, 3291–3302. [[CrossRef](#)]
12. Bahroudi, Z.; Zarnaghi, M.R.; Izadpanah, M.; Abedelahi, A.; Niknafs, B.; Nasrabadi, H.T.; Seghinsara, A.M. Review of ovarian tissue cryopreservation techniques for fertility preservation. *J. Gynecol. Obstet. Hum. Reprod.* **2022**, *51*, 102290. [[CrossRef](#)]
13. El Cury-Silva, T.; Nunes, M.E.G.; Casalechi, M.; Comim, F.V.; Rodrigues, J.K.; Reis, F.M. Cryoprotectant agents for ovarian tissue vitrification: Systematic review. *Cryobiology* **2021**, *103*, 7–14. [[CrossRef](#)] [[PubMed](#)]
14. Trapphoff, T.; Dieterle, S. Cryopreservation of Ovarian and Testicular Tissue and the Influence on Epigenetic Pattern. *Int. J. Mol. Sci.* **2023**, *24*, 11061. [[CrossRef](#)] [[PubMed](#)]
15. Cheng, H.; Han, Y.; Zhang, J.; Zhang, S.; Zhai, Y.; An, X.; Li, Q.; Duan, J.; Zhang, X.; Li, Z.; et al. Effects of dimethyl sulfoxide (DMSO) on DNA methylation and histone modification in parthenogenetically activated porcine embryos. *Reprod. Fertil. Dev.* **2022**, *34*, 598–607. [[CrossRef](#)] [[PubMed](#)]
16. Verheijen, M.; Lienhard, M.; Schroeders, Y.; Clayton, O.; Nudischer, R.; Boerno, S.; Timmermann, B.; Selevsek, N.; Schlapbach, R.; Gmuender, H.; et al. DMSO induces drastic changes in human cellular processes and epigenetic landscape in vitro. *Sci. Rep.* **2019**, *9*, 4641. [[CrossRef](#)]
17. Galvao, J.; Davis, B.; Tilley, M.; Normando, E.; Duchon, M.R.; Cordeiro, M.F. Unexpected low-dose toxicity of the universal solvent DMSO. *FASEB J.* **2014**, *28*, 1317–1330. [[CrossRef](#)]
18. Iwatani, M.; Ikegami, K.; Kremenska, Y.; Hattori, N.; Tanaka, S.; Yagi, S.; Shiota, K. Dimethyl sulfoxide has an impact on epigenetic profile in mouse embryoid body. *Stem Cells* **2006**, *24*, 2549–2556. [[CrossRef](#)]
19. Sugishita, Y.; Taylan, E.; Kawahara, T.; Shahmurzada, B.; Suzuki, N.; Oktay, K. Comparison of open and a novel closed vitrification system with slow freezing for human ovarian tissue cryopreservation. *J. Assist. Reprod. Genet.* **2021**, *38*, 2723–2733. [[CrossRef](#)]
20. Vajta, G.; Rienzi, L.; Ubaldi, F.M. Open versus closed systems for vitrification of human oocytes and embryos. *Reprod. Biomed. Online* **2015**, *30*, 325–333. [[CrossRef](#)]
21. Yang, Y.; Wang, Y.; Xiao, Z. Silver closed vitrification system versus slow freezing method for the cryopreservation of human ovarian tissue. *Cryo Lett.* **2021**, *42*, 245–250.
22. Baust, J.M.; Van Buskirk, R.; Baust, J.G. Modulation of the cryopreservation cap: Elevated survival with reduced dimethyl sulfoxide concentration. *Cryobiology* **2002**, *45*, 97–108. [[CrossRef](#)] [[PubMed](#)]
23. Owen, R.E.; Sinclair, E.; Emu, B.; Heitman, J.W.; Hirschhorn, D.F.; Epling, C.L.; Tan, Q.X.; Custer, B.; Harris, J.M.; Jacobson, M.A.; et al. Loss of T cell responses following long-term cryopreservation. *J. Immunol. Methods* **2007**, *326*, 93–115. [[CrossRef](#)] [[PubMed](#)]
24. Rosillo, M.C.; Ortuño, F.; Rivera, J.; Moraleda, J.M.; Vicente, V. Cryopreservation modifies flow-cytometric analysis of hemopoietic cells. *Vox Sang.* **1995**, *68*, 210–214. [[CrossRef](#)]
25. Brauchle, E.; Thude, S.; Brucker, S.Y.; Schenke-Layland, K. Cell death stages in single apoptotic and necrotic cells monitored by Raman microspectroscopy. *Sci. Rep.* **2014**, *4*, 4698. [[CrossRef](#)]
26. Kokotsaki, M.; Mairhofer, M.; Schneeberger, C.; Marschalek, J.; Pietrowski, D. Impact of vitrification on granulosa cell survival and gene expression. *Cryobiology* **2018**, *85*, 73–78. [[CrossRef](#)] [[PubMed](#)]
27. Chimento, A.; Sirianni, R.; Casaburi, I.; Ruggiero, C.; Maggiolini, M.; Ando, S.; Pezzi, V. 17beta-Estradiol activates GPER- and ESR1-dependent pathways inducing apoptosis in GC-2 cells, a mouse spermatocyte-derived cell line. *Mol. Cell. Endocrinol.* **2012**, *355*, 49–59. [[CrossRef](#)] [[PubMed](#)]
28. Marschalek, J.; Egarter, C.; Nouri, K.; Dekan, S.; Ott, J.; Frank, M.; Pietrowski, D. The effect of different vitrification protocols on cell survival in human ovarian tissue: A pilot study. *J. Ovarian Res.* **2021**, *14*, 170. [[CrossRef](#)] [[PubMed](#)]
29. Baust, J.M.; Campbell, L.H.; Harbell, J.W. Best practices for cryopreserving, thawing, recovering, and assessing cells. *Vitr. Cell. Dev. Biol. Anim.* **2017**, *53*, 855–871. [[CrossRef](#)]
30. Heng, B.C. Effect of Rho-associated kinase (ROCK) inhibitor Y-27632 on the post-thaw viability of cryopreserved human bone marrow-derived mesenchymal stem cells. *Tissue Cell* **2009**, *41*, 376–380. [[CrossRef](#)]
31. Li, X.; Krawetz, R.; Liu, S.; Meng, G.; Rancourt, D.E. ROCK inhibitor improves survival of cryopreserved serum/feeder-free single human embryonic stem cells. *Hum. Reprod.* **2009**, *24*, 580–589. [[CrossRef](#)] [[PubMed](#)]
32. Liu, W.; Zhang, J.; Wang, L.; Liang, S.; Xu, B.; Ying, X.; Li, J. The protective effects of rapamycin pretreatment on ovarian damage during ovarian tissue cryopreservation and transplantation. *Biochem. Biophys. Res. Commun.* **2021**, *534*, 780–786. [[CrossRef](#)] [[PubMed](#)]
33. Youm, H.S.; Choi, J.R.; Oh, D.; Rho, Y.H. Survival Rates in Closed and Open Vitrification for Human Mature Oocyte Cryopreservation: A Meta-Analysis. *Gynecol. Obstet. Investig.* **2018**, *83*, 268–274. [[CrossRef](#)] [[PubMed](#)]
34. Youm, H.S.; Choi, J.R.; Oh, D.; Rho, Y.H. Closed versus open vitrification for human blastocyst cryopreservation: A meta-analysis. *Cryobiology* **2017**, *77*, 64–70. [[CrossRef](#)] [[PubMed](#)]
35. Silber, S.J.; DeRosa, M.; Goldsmith, S.; Fan, Y.; Castleman, L.; Melnick, J. Cryopreservation and transplantation of ovarian tissue: Results from one center in the USA. *J. Assist. Reprod. Genet.* **2018**, *35*, 2205–2213. [[CrossRef](#)]
36. Oktem, O.; Alper, E.; Balaban, B.; Palaoglu, E.; Peker, K.; Karakaya, C.; Urman, B. Vitrified human ovaries have fewer primordial follicles and produce less antimullerian hormone than slow-frozen ovaries. *Fertil. Steril.* **2011**, *95*, 2661–2664.e2661. [[CrossRef](#)]

37. Lew, M. Good statistical practice in pharmacology. Problem 2. *Br. J. Pharmacol.* **2007**, *152*, 299–303. [[CrossRef](#)]
38. Kenmotsu, M.; Matsuzaka, K.; Kokubu, E.; Azuma, T.; Inoue, T. Analysis of side population cells derived from dental pulp tissue. *Int. Endod. J.* **2010**, *43*, 1132–1142. [[CrossRef](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.